Trial Information
Current as of March 14, 2025
Completed
Keywords
ClinConnect Summary
The primary objective of the trial is to estimate the frequency of Major Adverse Cardiac Events (MACE), including cardiac death, myocardial infarction within the territory of the treated lesion, and revascularization of the target lesion in a representative population of patients treated by coronary angioplasty of type 0-0-1 bifurcation lesions.
The sample size will be determined by the number of angioplasties of type 0-0-1 bifurcation lesions performed at each center between 2016 and 2022.
Since the trial is observational in nature and there are no previously published studies, the sampl...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female aged 18 years and older,
- • Who underwent angioplasty for a coronary bifurcation lesion of type 0-0-1 between 2016 and 2022.
- Exclusion Criteria:
- • - Opposing the collection and processing of necessary data and refusing additional telephone follow-up
Trial Officials
Francesca SANGUINETI, MD
Principal Investigator
ICPS
About Rcf@Icps
RCF@ICPS is a leading clinical trial sponsor dedicated to advancing medical research and innovation through rigorous study design and execution. With a focus on enhancing patient outcomes and safety, RCF@ICPS collaborates with healthcare professionals, institutions, and regulatory bodies to conduct high-quality clinical trials across various therapeutic areas. Our commitment to ethical practices and data integrity ensures that our studies contribute valuable insights to the medical community, ultimately driving the development of effective treatments and improving public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toulouse, , France
Rotterdam, , Netherlands
Massy, , France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
